User profiles for H. Butzkueven
Helmut ButzkuevenMSNI Research Group, Dept of Neuroscience, School of Translational Medicine, Monash … Verified email at monash.edu Cited by 24105 |
[HTML][HTML] Brain health: time matters in multiple sclerosis
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
[HTML][HTML] Epigenome-wide association studies: current knowledge, strategies and recommendations
The aetiology and pathophysiology of complex diseases are driven by the interaction between
genetic and environmental factors. The variability in risk and outcomes in these diseases …
genetic and environmental factors. The variability in risk and outcomes in these diseases …
Treatment decisions in multiple sclerosis—insights from real-world observational studies
…, T Spelman, MP Sormani, H Butzkueven - Nature Reviews …, 2017 - nature.com
The complexity of multiple sclerosis (MS) treatment means that doctors and decision-makers
need the best available evidence to make the best decisions for patient care. Randomized …
need the best available evidence to make the best decisions for patient care. Randomized …
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
Background: There is no consensus method for determining progression of disability in patients
with multiple sclerosis (MS) when each patient has had only a single assessment in the …
with multiple sclerosis (MS) when each patient has had only a single assessment in the …
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
…, I Buraga, M Burnett, M Buttmann, H Butzkueven… - The Lancet, 2018 - thelancet.com
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
…, L Blizzard, R Simmons, BV Taylor, H Butzkueven… - Bmj, 2003 - bmj.com
Objective To examine whether past high sun exposure is associated with a reduced risk of
multiple sclerosis. Design Population based case-control study. Setting Tasmania, latitudes 41…
multiple sclerosis. Design Population based case-control study. Setting Tasmania, latitudes 41…
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
…, TJ Kilpatrick, H Butzkueven… - Multiple Sclerosis …, 2006 - journals.sagepub.com
This study evaluated the gait and balance performance of two clinically distinct groups of
recently diagnosed and minimally impaired multiple sclerosis (MS) patients (Expanded …
recently diagnosed and minimally impaired multiple sclerosis (MS) patients (Expanded …
Defining secondary progressive multiple sclerosis
…, O Gray, C Shaw, F Moore, H Butzkueven… - Brain, 2016 - academic.oup.com
A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
…, K Harding, J Jones, C McGuigan, H Butzkueven… - Jama, 2019 - jamanetwork.com
… Dr Butzkueven reported serving on the Australian and global advisory boards of and
receiving lecture fees from Novartis, Biogen, and Merck; consultancy fees from Oxford …
receiving lecture fees from Novartis, Biogen, and Merck; consultancy fees from Oxford …